ADVOCACY PROJECT
Bringing patient voices into the conversations that shape cancer care.
Radioligand therapy is changing how certain cancers can be treated, yet access across Europe remains uneven. Reimbursement rules differ from one country to the next, awareness among referring doctors varies, and nuclear medicine infrastructure is unequally distributed. For people living with cancer, these gaps can mean travelling far from home, waiting too long, or never hearing about radioligand therapy at all.
At the Oncidium foundation, we bring these realities into the conversations that matter, engaging with European institutions and national authorities to share patient experiences and work with partners on solutions.
At the European Parliament
On 9 April 2025, our CEO, Rebecca Lo Bue joined the panel "European and National RLT Policy & Reality" at the European Parliament, co-hosted by MEPs Tomislav Sokol and Nicholas Papandreou. We thank SPARC Europe for the invitation.
Drawing on the journey of one person living with cancer, Rebecca illustrated how a healthcare system can fall short at several points, and what this means for the individual and their family. She called for three priorities: harmonised referral pathways across Europe, cross-border collaboration between healthcare systems, and targeted investment in nuclear medicine.
The Oncidium foundation supports access to treatment for people in need, and we believe healthcare systems can evolve to better serve them. Acting earlier, with the most appropriate treatment, improves quality of life and makes better use of healthcare resources.
A continued commitment
Alongside our ambassadors and partners, the Oncidium foundation will keep showing up in these spaces because breakthrough therapies only matter when they reach the people who need them.